Temozolomide (TMZ) is an alkylating agent widely used in the treatment of glioblastoma multiform and other malignant brain tumors. However, the commercially available capsule dosage form presents challenges in pediatric, geriatric, and dysphagia patients due to swallowing difficulty and dose inflexibility. The present study aims to develop and evaluate a stable, patient-friendly oral suspension of temozolomide using a Quality-based pharmaceutics approach. A novel citrate-buffered, polymer-stabil